Anna is a seasoned Regulatory Affairs professional, specializes in cell and gene therapies within the field of immuno-oncology. Her expertise lies in strategic regulatory planning, navigating expedited programs, orphan designations, and fostering effective interactions with FDA, EMA and other regulatory authorities.